Home›Oncology› HER2-low breast cancer shows distinct survival trajectories versus HER2-positive in systematic review
HER2-low breast cancer shows distinct survival trajectories versus HER2-positive in systematic reviewHER2-Low Status Shows Distinct Survival Paths in Breast Cancer
Frontiers in MedicinePublished September 11, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Recognize that HER2-low breast cancer may have distinct survival trajectories versus HER2-positive, but evidence is qualitative.
This systematic review examined survival outcomes in patients with HER2-low and HER2-positive breast cancer across 10 trials. The authors focused on progression-free survival (PFS) and overall survival (OS) as the primary and secondary outcomes, respectively.
The review reports that HER2-low tumors exhibit distinct survival trajectories compared with HER2-positive cohorts for both PFS and OS. However, no effect sizes, absolute numbers, or p-values or confidence intervals were reported for these comparisons. The direction of the difference was not specified.
Because of significant clinical and methodological heterogeneity, the authors deemed a formal meta-analysis inappropriate and instead conducted a qualitative synthesis using SWiM (Synthesis Without Meta-analysis) methodology. This limits the precision and comparability of the findings.
Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported. Follow-up duration was also not reported. Funding sources and conflicts of interest were not disclosed.
The authors note that understanding these survival disparities is crucial for optimizing treatment sequencing in the era of antibody-drug conjugates (ADCs). However, given the qualitative nature of the synthesis and the absence of quantitative effect estimates, the findings should be interpreted as hypothesis-generating rather than definitive.
How this fits prior evidence
This systematic review addresses a gap in prior coverage, which has focused on surgical techniques, immune cell quantification, exercise interventions, and radiation fractionation in breast cancer. None of the prior items directly compared survival outcomes between HER2-low and HER2-positive subtypes. The finding that HER2-low tumors exhibit distinct survival trajectories extends the evidence base by highlighting a subtype-specific prognostic difference, but the qualitative synthesis and lack of effect sizes mean it does not confirm or contrast with prior quantitative findings. It may inform future treatment sequencing discussions in the context of ADCs.
Researchers reviewed 10 trials to compare how patients with HER2-low and HER2-positive breast cancer respond to treatment. The study looked specifically at how long patients lived without their cancer progressing and their overall survival rates.
The results showed that HER2-low tumors have distinct survival trajectories compared to HER2-positive tumors. This finding is important because it helps doctors understand how different types of breast cancer behave over time. This information is especially useful when choosing the right sequence of treatments, such as antibody-drug conjugates.
Because the trials involved very different methods and patient groups, the results should be viewed with caution. The study is a qualitative synthesis rather than a strict mathematical calculation. While the findings highlight important differences in survival, they do not provide a specific recommendation for every patient. Patients should talk to their doctors about how these findings apply to their specific diagnosis.
What this means for you:
HER2-low and HER2-positive breast cancer tumors show different survival patterns, which may help guide treatment.
Common questions
What is the difference between HER2-low and HER2-positive breast cancer?
The study looked at how these two types of breast cancer behave differently. It found that HER2-low tumors show distinct survival trajectories compared to HER2-positive tumors. This difference is important for doctors when they are deciding on the best sequence of treatments for their patients.
How does this finding help with breast cancer treatment?
Understanding the different survival paths for HER2-low and HER2-positive tumors helps doctors optimize treatment plans. This is especially important in the era of antibody-drug conjugates, as it helps them choose the most effective timing for various therapies.
Is this finding a definitive guide for my treatment?
This study is a qualitative synthesis of 10 trials and showed significant differences in how the trials were conducted. Because of this variety, the results are not a specific medical recommendation. You should speak with your doctor to discuss how these findings apply to your specific case.
BackgroundThe emergence of HER2-low breast cancer as a distinct clinical entity has challenged the traditional binary classification of HER2 status. This systematic review aims to evaluate the disparities in Progression-Free Survival (PFS) and Overall Survival (OS) between HER2-low and HER2-positive breast cancer patients.MethodsA systematic search was performed across PubMed, Scopus, Cochrane Library, ESMO and ASCO for studies published through January 2026. The Clinical trials and observational studies reporting Progression-Free Survival (PFS) and Overall Survival (OS) with Hazard Ratios (HR) were included. Due to significant clinical and methodological heterogeneity, a formal meta-analysis was deemed inappropriate; consequently, evidence was synthesized qualitatively following the Synthesis Without Meta-analysis (SWiM) guidelines. The protocol was prospectively registered in PROSPERO (CRD420261293004).ResultsA total of 536 records were identified; after removing 356 duplicates, 180 were screened, and 10 trials met the inclusion criteria. Preliminary synthesis indicates that HER2-low tumors exhibit distinct survival trajectories compared to HER2-positive cohorts, often influenced by Hormone Receptor (HR) co-expression and the type of targeted therapy received.ConclusionUnderstanding survival disparities is crucial for optimizing treatment sequencing in the era of antibody-drug conjugates (ADCs).Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD420261293004.
